190 related articles for article (PubMed ID: 36647599)
1. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Nishikawa R; Yamasaki F; Arakawa Y; Muragaki Y; Narita Y; Tanaka S; Yamaguchi S; Mukasa A; Kanamori M
Jpn J Clin Oncol; 2023 Apr; 53(5):371-377. PubMed ID: 36647599
[TBL] [Abstract][Full Text] [Related]
2. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
3. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
4. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
5. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
8. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
9. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
10. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
11. Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19).
Zhu JJ; Goldlust SA; Kleinberg LR; Honnorat J; Oberheim Bush NA; Ram Z
Discov Oncol; 2022 Oct; 13(1):105. PubMed ID: 36239858
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
13. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
14. Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
Mikic N; Poulsen FR; Kristoffersen KB; Laursen RJ; Guldberg TL; Skjøth-Rasmussen J; Wong ET; Møller S; Dahlrot RH; Sørensen JCH; Korshøj AR
BMC Cancer; 2021 Sep; 21(1):1010. PubMed ID: 34503460
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
16. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Saria MG; Kesari S
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388
[TBL] [Abstract][Full Text] [Related]
19. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]